Cellectis S.A. (CLLS) has released an update.
Cellectis S.A., a biotechnology firm specializing in gene-editing for cancer treatments, has announced the immediate departure of CFO Bing Wang and the appointment of Arthur Stril as the interim CFO. Stril, who has been with the company since 2018, previously led Cellectis’ strategic collaborations, including a significant partnership with AstraZeneca. His extensive experience in the industry is expected to support Cellectis’ advancement into pivotal clinical trials and the continued development of innovative cell and gene therapies.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.